[go: up one dir, main page]

MX2017004764A - Formulacion de polvo seco. - Google Patents

Formulacion de polvo seco.

Info

Publication number
MX2017004764A
MX2017004764A MX2017004764A MX2017004764A MX2017004764A MX 2017004764 A MX2017004764 A MX 2017004764A MX 2017004764 A MX2017004764 A MX 2017004764A MX 2017004764 A MX2017004764 A MX 2017004764A MX 2017004764 A MX2017004764 A MX 2017004764A
Authority
MX
Mexico
Prior art keywords
dry powder
powder formulation
inhaler
heating
wrapper
Prior art date
Application number
MX2017004764A
Other languages
English (en)
Inventor
Dalvi Mukul
Kee Tee Seah
Original Assignee
Teva Branded Pharmaceutical Products R&D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017004764(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Products R&D Inc filed Critical Teva Branded Pharmaceutical Products R&D Inc
Publication of MX2017004764A publication Critical patent/MX2017004764A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención proporciona un proceso para preparar una formulación farmacéutica de polvo seco inhalable que comprende la etapa de calentar una envoltura sellada que contiene un desecante y un inhalador o una cápsula, el inhalador o cápsula que contiene, además, una formulación de polvo seco que comprende un ingrediente farmacéutico activo inhalable y un portador, en el que la envoltura forma una barrera a la entrada de humedad y en donde el calentamiento de la envoltura sellada y su contenido se lleva a cabo a una temperatura de 30-50 °C.
MX2017004764A 2014-10-16 2015-10-16 Formulacion de polvo seco. MX2017004764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064690P 2014-10-16 2014-10-16
PCT/US2015/055919 WO2016061448A1 (en) 2014-10-16 2015-10-16 Dry powder formulation

Publications (1)

Publication Number Publication Date
MX2017004764A true MX2017004764A (es) 2017-07-27

Family

ID=54427855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004764A MX2017004764A (es) 2014-10-16 2015-10-16 Formulacion de polvo seco.

Country Status (15)

Country Link
US (1) US9980904B2 (es)
EP (1) EP3206668A1 (es)
JP (1) JP6653324B2 (es)
KR (1) KR20170068571A (es)
CN (1) CN107106514A (es)
AR (1) AR102305A1 (es)
AU (1) AU2015331915A1 (es)
BR (1) BR112017007587A2 (es)
CA (1) CA2963146A1 (es)
CO (1) CO2017004787A2 (es)
EA (1) EA201790833A1 (es)
IL (1) IL251665A0 (es)
MX (1) MX2017004764A (es)
PE (1) PE20170690A1 (es)
WO (1) WO2016061448A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790832A1 (ru) * 2014-10-16 2017-09-29 Тева Брэндид Фармасьютикал Продактс Ар Энд Ди, Инк. Ингалируемый состав
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
PT3833964T (pt) 2018-08-07 2023-08-17 Norton Waterford Ltd Aplicação de espetroscopia de raman para o fabrico de pós de inalação
CN116615201A (zh) 2020-08-14 2023-08-18 诺顿（沃特福特）有限公司 丙酸氟替卡松和硫酸沙丁胺醇的可吸入制剂
GB202012742D0 (en) * 2020-08-14 2020-09-30 Norton Waterford Ltd An inhalable medicament
US12029709B2 (en) * 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
GB9526392D0 (en) * 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
SE0303570L (sv) 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
CA2547245A1 (en) * 2003-12-03 2005-06-16 Microdrug Ag Pre-metered dry powder inhaler for moisture-sensitive medicaments
CA2554136C (en) 2004-02-24 2013-05-28 Microdose Technologies, Inc. Synthetic jet based medicament delivery method and apparatus
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US8196576B2 (en) 2007-02-28 2012-06-12 Microdose Therapeutx, Inc. Inhaler
PE20090907A1 (es) 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
CA2963666A1 (en) * 2014-10-08 2016-04-14 Pulmatrix Operating Company, Inc. Formulations containing tiotropium, amino acid and acid and methods thereof

Also Published As

Publication number Publication date
BR112017007587A2 (pt) 2018-01-30
US9980904B2 (en) 2018-05-29
JP2017530995A (ja) 2017-10-19
US20170239177A1 (en) 2017-08-24
AU2015331915A1 (en) 2017-05-25
EA201790833A1 (ru) 2017-09-29
PE20170690A1 (es) 2017-05-25
CA2963146A1 (en) 2016-04-21
JP6653324B2 (ja) 2020-02-26
WO2016061448A1 (en) 2016-04-21
AR102305A1 (es) 2017-02-15
EP3206668A1 (en) 2017-08-23
CN107106514A (zh) 2017-08-29
CO2017004787A2 (es) 2017-09-20
KR20170068571A (ko) 2017-06-19
IL251665A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
MX2017004764A (es) Formulacion de polvo seco.
MX392436B (es) Formulaciones de cannabinoide.
PH12016500547A1 (en) Aerosol-generating system comprising a cylindrical polymeric capsule
IL247722A0 (en) Pharmaceutical compositions of therapeutically active compounds for treating hematolugic cancer
PT3674298T (pt) Indazóis substituídos, métodos para a sua produção, preparações farmacêuticas que contêm os mesmos e sua utilização para produção de medicamentos
WO2014147611A8 (en) Quinolines derivatives as novel anticancer agents
PH12016502248A1 (en) Adenoassociated virus vectors for the treatment of lysosomal storage disorders
IL275220B1 (en) Oral administration of active pharmaceutical ingredients
IL272637A (en) History of benzaimidazole, their preparation and medicines containing them
CY1124490T1 (el) Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο
HUP1400075A2 (hu) Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
WO2014121764A3 (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
EA201791632A1 (ru) Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат
NZ728401A (en) High purity oritavancin and method of producing same
WO2013104892A8 (en) Application of high dose compounds via inhalation
JOP20200053A1 (ar) تركيبات كوبانليسيب
IL272806A (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
SG11201610636VA (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
HUE053710T2 (hu) H3-ligand-tetrahidrát, eljárás elõállítására és H3-ligand-tetrahidrátot tartalmazó gyógyászati készítmények
IN2014DE00111A (es)
GR1008442B (el) Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
EA201790832A1 (ru) Ингалируемый состав
IL262490A (en) Lomacaptor complexes and their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them